New statisticians entering industry tend to "test statistical interactions" whenever there is a need. However, in many real-world applications, especially in clinical development of new drugs, most interactions need to be estimated, instead of tested. In this manuscript, the distinction between hypothesis testing and estimation will be articulated, and the use of statistical interactions in clinical development programs will be discussed. According to ICH E-9, the treatment by subgroup interaction should not be included in the prespecified primary statistical analysis model. The reasons behind this ICH E-9 recommendation are also clarified in this manuscript.
Statistical interactions are not easily comprehensible to nonstatisticians. In a statistical analysis of clinical trial data where a test intervention is compared against a placebo control, if there is an interest in studying subgroup analysis by gender, then a treatment by gender interaction may be observed. When this is the case, the interpretation of such a statistical interaction can be as follows: "treatment benefit for male patients is different from treatment benefit for female patients." Typically 2 types of interactions can be detected: (1) a quantitative interaction indicates that patients who took the test drug experienced more improvement than placebo, in both genders. However, the treatment benefit for male and female patients are different ( Figure 1A ). Another type is (2) a qualitative interaction implying that the improvement of male patients and female patients progressed in different directions. Figure 1B shows that male patients benefit from the test treatment, while female patients benefit from the control (or it could be interpreted that the test treatment may be harmful to female patients).
For most statisticians, an interaction tends to be understood as "lack of parallelism." In other words, if there is no interaction, then the line segments should be parallel. (As can be seen from Figures 1A and 1B, in both cases, the line segments are not parallel.) In statistical modeling, the text book approach is, "First include the interaction in the model and test this interaction. If it is not significant, then drop the interaction term and re-fit the model with only main effects. If the interaction is significant, then the main effect cannot be directly interpretable." Do the interaction terms have to be in the model at the first place? From an experiment design point of view, sample size calculation is typically based on the expected treatment difference, the prespecified type I and type II error rate. Very rarely is a study designed with the primary objective of testing the treatment by factor interaction. On this basis, the prespecified alpha (type I error rate) should be allocated to treatment comparison. When this is the case, is there any alpha left to test for interaction?
In statistical applications, most of the time a statistician is working with nonstatistical team members. Under this circumstance, communications of statistical concepts to nonstatistician becomes a critical part of responsibilities for applied statisticians. One necessary condition for a successful applied statistician is the communication skills. This is especially true in application of statistics to clinical trials. In our opinion, the 2 most important contributions a clinical statistician makes to the study team are statistical consulting and trial design. Thus, communication skill is key to a clinical statistician's success. In clinical development of new medicinal products, study design plays a very important role in addressing critical development questions. One poor study design could easily cost millions or tens of millions of dollars of investment, leading to ambiguous clinical results and creating major delays in product registration. The objective of this manuscript is to clarify some of the confusing issues and propose simple solutions to some of the practical clinical questions. Statistical interaction touches on both statistical consulting and clinical trial design.
Confirm and Explore
In clinical development of new medicinal products, a trial is usually designed with a primary clinical question that needs to be addressed. The statistician works with the clinician and/or other core clinical trial team members to formulate this question into a statistical hypothesis, and then, based on this hypothesis, the sample size can be calculated. Typically, after the clinical trial is completed and data are available for review, many other questions could also be raised and the clinical results are discussed and debated among team members, as well as communicated with upper managements.
During the discussion of study results, other than the primary confirmative hypothesis, many of the questions tend to be exploratory in nature. From a statistical point of view, confirmatory questions can be addressed by use of hypothesis testing, and exploratory questions are usually dealt with estimationpoint estimation, interval estimation, or both. However, in clinical results discussion, we often hear statements like "We need to make a decision about. . . . " At such times, some junior statisticians could be confused-if a decision needs to be made, then the question could be confirmatory; hence, a P value might be useful. This confusion creates many difficulties in overuse of P values. The overuse and overinterpretation of P values has been discussed in an American Statistical Association statement. 1 In applications of statistics in the clinical development of new drugs, overuse and overinterpretation of P values happen frequently, and it takes a clinical statistician to help clarify these points to those nonstatisticians. Ting 2 explained that the thinking process in designing clinical trials involves a confirmatory step and an exploratory step. In a randomized, controlled, blinded clinical trial, the randomization allows an alpha (type I error) to be used in decision making. Statistical procedures used for data analyses should be selected so that this experiment-wise type I error rate is not inflated. Hence the primary objective of a clinical trial is expressed as a statistical hypothesis and the pre-specified alpha is used to test this hypothesis. Sample size is calculated according to the pre-specified treatment difference, alpha and power. P values obtained from this statistical hypothesis test will then be used to confirm whether this primary objective of the study was achieved. It is critical to note that in order to protect this alpha such that it is not artificially inflated, the simplest way is to perform data analysis using the prespecified primary endpoint, under the primary comparisons, with the primary time point and primary set of patients (typically the intention-totreat patient set).
Also important is that the analysis be based on the prespecified statistical model. On this basis, there typically is not much room for model selection because any model selection could potentially trigger alpha inflation. In this case, the statistical textbook approach of "including interaction first, and then depending on the significance of interaction term, the next model will be used for primary analysis" may not be able to protect the experiment-wise type I error (alpha) from being inflated. Hence the ICH-E9 3 makes the following statement:
ICH-E9
The statistical model to be adopted for the estimation and testing of treatment effects should be described in the protocol. The main treatment effect may be investigated first using a model that allows for center differences, but does not include a term for treatment-bycenter interaction. If the treatment effect is homogeneous across centers, the routine inclusion of interaction terms in the model reduces the efficiency of the test for the main effects. In the presence of true heterogeneity of treatment effects, the interpretation of the main treatment effect is controversial.
These sentences imply that the primary analytical model include center as a main effect but not to include the interaction term. Note that back in the 1990s, it was common to look at center effects. In many of the current clinical trials, centers are not considered as an important stratification factor. Although the ICH-E9 uses the term "center" in many statements, when this term is replaced with "stratification factor," all discussions are still applicable to the recent clinical trials.
The process briefly discussed above serves as a confirmatory practice. However, in most clinical trials, additional questions can be asked about the trial results. These additional questions are usually not alpha-protected. From this point of view, those non-alpha-protected questions can be thought of as exploratory questions. Examples of these questions include subgroup analysis, dose-response relationship, safety analyses, sensitivity analyses, etc. Statistical methods dealing with exploratory questions are mainly based on estimation-point or interval estimates such as mean, rate, slope, adjusted area under the curve, and others. Hence in most cases there is no P value associated with these exploratory questions. In clinical trial applications, statistical interactions are often studied to help with understanding of treatment effects among subgroups. Hence, discussions of this manuscript will be focused on subgroup analyses. It is generally understood 4 that for subgroup analyses, reporting P values in treatment comparisons within each subgroup is not appropriate. However, not much was mentioned about interactions. Because the nature of subgroup analysis is exploratory, the assessment of interaction could also be considered as exploratory. On this basis, testing statistical interaction may not be most appropriate. The primary hypothesis is to compare treatment effect based on the efficacy endpoint of all patients. The entire alpha is used on this comparison, and hence there is no prespecified alpha left to test for interaction. Given this understanding, evaluation of statistical interaction should be estimation, not hypothesis testing. Therefore, from the clinical trial design point of view, it can be stated that treatment effects within subgroups will be explored, and interactions will be estimated.
In a clinical trial comparing 2 treatments in a study stratified by gender, there is only 1 degree of freedom for treatment by gender interaction. Hence the point estimate and interval estimate can be performed on the contrast:
where m 11 is the mean of treatment 1, gender 1; m 12 is the mean of treatment 1, gender 2; m 21 is the mean of treatment 2, gender 1; and m 22 is the mean of treatment 2, gender 2.
The literature highlights that the presence and the size of interaction depends on the choice of the measure of divergence between the treatment groups. 5, 6 In clinical trial applications when a statistical interaction is contemplated, project teams are interested in finding out whether this interaction is a quantitative interaction, or a qualitative interaction. Quantitative interactions may trigger further discussions depending on the magnitude of treatment benefit experienced by patients within each subgroup. However, in the case of qualitative interactions being observed, the regulators may consider restricting the product approval to only certain subgroups of patients, or apply a warning in the drug label.
Analysis of Covariance and Mixed Model With Repeated Measures
In the analysis of continuous data, typical methods include analysis of variance, regression, and analysis of covariance. For data collected over time, longitudinal analytical models could also be considered. Again, only 1 statistical model can be prespecified as the primary analysis model. This model needs to be clearly described so that when the statistical reviewers in regulatory agencies attempt to replicate the sponsor's analysis on the same data set, by using the model specified in the protocol, or in the statistical analysis plan (SAP), they can obtain identical results as those presented in the clinical study report submitted by the sponsors.
Model specification should clearly describe how the primary endpoint is calculated. Is it change from baseline or simply the post baseline outcome? Are covariates included in the model? For longitudinal data, what variance-covariance structure is assumed for the residuals over time for each subject? Since only 1 primary model can be pre-specified, this implies that in the primary analysis of clinical trials, there will be no "model selection." This concept follows the principle of "analysis respects design."
For example, a widely accepted statistical model for analysis of a continuous primary endpoint is an ANCOVA with treatment effect, stratification factor, and the continuous baseline as a covariate, as follows:
where Y ijk is the response of the kth subject from the ith treatment group with baseline stratum level j. i ¼ 1, . . . , I; j ¼ 1, . . . J; and k ¼ 1, . . . , n ij , where m is the overall mean t i is the ith treatment effect, g j is the jth stratum effect, b is the slope associated with the baseline measure, X ijk is the baseline corresponding to the kth patient in ith treatment of kth stratum, and e ijk is the residual of this subject.
In this example, a stratification factor is included in the model as a covariate. Typically, stratification factors are accepted as potential covariates in the primary analysis model. In recent years, center effect became a less popular factor in clinical trials. However, in some situations when the physician assessment of disease activity is more subjective, then it is sensible to include center or investigator as a covariate in the primary model. However, if the assessment is more objective, then the clinical trial team may not want to include this effect in the model because it usually takes away a large number of degrees of freedom.
In most protocols or statistical analysis plans, the description of the primary analysis model may include the main effects of treatment, stratification factor, and baseline covariate of the outcome (dependent) variable as a continuous covariate, without any interaction terms. However, in sensitivity analysis or exploratory analysis, treatment-by-factor interaction terms could be considered in the model. There could be at least 3 reasons to consider this interaction as exploratory and hence not prespecified in the primary analytical model:
1. the primary objective is to study the entire subject population, not any particular subgroups; 2. a model selection process could potentially inflate the study-wise type I error; and 3. there is no prespecified alpha for testing the treatmentby-factor interaction.
The first reason has been clarified in the ICH-E9. In other words, at the study design stage, the expectation is that the test product be superior to the placebo control across all subgroups. Again, the objective, or the designed feature, is not to "confirm" any interaction or any treatment benefit to a particular subgroup. Any treatment-by-subgroup interaction or subgroup treatment effect can be considered only as an "observed feature" (as opposed to a "designed feature"). Nevertheless, if it is not known at the design stage whether any subgroup may benefit more from this test treatment, the treatment effect in subgroups or the treatment-by-subgroup interactions can be explored. In case it is already known that the study treatment benefits a particular subgroup, then phase III clinical trials may be designed to only confirm treatment efficacy for this welldefined subgroup. For example, if the team believes that the study drug only benefits female patients, then the clinical study should be designed to recruit only females. Here protocol inclusion/exclusion criteria would reflect the selection of those subjects of interests. On this basis, at the design stage, there is no need of a treatment-by-subgroup interaction in the primary statistical analysis model.
From the alpha protection perspective, any model selection process could potentially inflate alpha. Suppose that 2 models are considered as candidates for the primary analysis. After data readout, one model shows a statistical significance in the primary treatment comparison whereas the other fails to do that. A question arises as to which result should be used to make the decision from this given clinical trial. Therefore, a recommended process of including a treatment-by-subgroup interaction term in the initial model and, then after it is decided that the interaction is not statistically significant (note that there is no prespecified alpha for this statistical hypothesis), dropping this term from the model (in favor of reanalyzing the same data without such an interaction term) could potentially inflate alpha in practice. This approach is not applicable in designing clinical trials where the primary objective is to demonstrate clinical efficacy across all participating subjects. Hence, the second point from above indicates that, in practice, model selection is not appropriate under the given study design.
The third reason is about prespecified alpha in regard to the interpretation of a "treatment-by-factor" interaction test. If an interaction is included in the primary model, what P value offers a "significant interaction"? Does an observed P value of .06 imply that there is no treatment-by-subgroup interaction? In case an alpha is allocated to test for such an interaction, how should this alpha be used? Should the alpha for the interaction test be split and the rest used to test for the main treatment effect? Does a significant interaction reflect a prespecified alpha?
All of the above discussions point to a simple understanding that the treatment-by-subgroup interaction, by nature, is an exploratory phenomenon in a trial; it is not likely to be a confirmatory practice. This aspect is part of an observed feature in any given clinical study, as the interaction test does not appear to be a designed feature. On this basis, the exploration of a treatment-by-subgroup interaction can be achieved by estimation, instead of hypothesis testing.
The mixed model with repeated measures (MMRM) has become a popular model in analyzing longitudinal clinical data. 7 When this is used as the primary model, another term-visit-is included as a categorical covariate in the primary analysis model (as compared to the ANCOVA model). Accordingly, a treatment-by-visit interaction, as well as baseline covariate (of outcome)-by-visit interaction term, may be added to this model. The interpretation of these terms are very different from the interpretation of the treatment-by-subgroup interaction. Note that if the model does not include a treatmentby-visit interaction, it implies a strong assumption that the treatment differences are constant across visits. If the team is not willing to make such a strong assumption, then a treatmentby-visit interaction is necessary in this longitudinal model. The considerations, of course, are very different from those for the treatment by subgroup interaction.
When a treatment-by-visit interaction is added to this model, what does this interaction mean? Suppose a very simple model includes only the main effect of treatment and main effect of visit (without a treatment by visit interaction). Then the estimate of treatment provides information regarding the responses to each treatment group and treatment differences between groups of interest, across all visits. The estimate of a visit effect offers estimates at each visit across all treatment groups. In practice, for an MMRM analysis, the primary interest is typically a treatment benefit at the primary time point of interest. Such a model (without interaction) assumes treatment effects are constant over time; that is, treatment benefit at the first visit postbaseline is the same as the second visit postbaseline, and the same as the primary time point for efficacy analysis.
Suppose a trial is designed with monthly visit, and the primary time point is at month 6. Under such a study design, the assumption would be that the treatment benefit of test product as compared to the placebo control improves over time, and that up to month 6, such a benefit would be clinically meaningful. In other words, it is not expected that the treatment benefit at month 1 is strong enough and, in addition, that patients will need to be exposed to the test product over 6 months to experience the full benefit of such a product. A treatment-by-visit interaction allows the treatment benefits to change over time (visits). Hence, by adding this interaction term, the model users are relaxing an assumption of a constant treatment effect over time. Doing so is more realistic and less restrictive.
A baseline-by-visit interaction implies that the impact of baseline to responses at different visits could be different. Again, in a 6-month trial with only main fixed effects of treatment, visit and baseline covariate of outcome, without any interaction term, the implication is that the baseline effect to patient responses at the 1 month visit is the same as that at the 6 months after randomization. In common analytical models using baseline of outcome as a covariate, the assumption is that the baseline value is correlated to corresponding values in postbaseline outcomes differently at different visits. Typically the objective of a longitudinal clinical trial is to focus on treatment comparisons at the primary time point of analysis. Hence, an interaction term helps the fixed effect estimate at the primary time point not being averaged out across visits.
On this basis, it can be understood that the treatment-byvisit interaction, as well as the baseline-by-visit interaction, is part of the designed feature associated with a longitudinal study. Including these terms in the MMRM for the primary analysis is scientifically justified. It is also noteworthy that there is no model selection activities in such an MMRM as the interaction terms remain in the primary model regardless of the corresponding observed P values for these terms.
The understanding of treatment-by-subgroup interaction is exploratory in nature. It is generally not recommended to include such a term in the primary analytical model. However, in a secondary analytical model, both the interaction analysis and the subgroup analysis are viewed as exploratory. Estimation procedures can be appropriately applied to learn these results. Point estimates, along with confidence intervals (CIs), can be constructed on the parameter of interests. For subgroup analyses, descriptive statistics can be very useful. For treatment-by-subgroup interaction, whenever a particular single-degree of freedom interaction needs to be studied, point estimate and CIs can be established. For example, if there are only 2 treatment groups and 2 subgroups, where m ij represents the subgroup mean of the ith treatment and jth subgroup-then the interaction can be expressed as m 11 -m 12 -m 21 þ m 22 , after which the point estimate and interval estimate can be obtained for this contrast. In practice, an interaction contrast with 1 degree of freedom can be implemented using a simple 1-way analysis of variance model with 4 groups denoted as the 11, 12, 21, and 22 group.
Subgroup Analysis
A typical study design is usually with a confirmatory objective. This is especially true in clinical trials. Oftentimes the objective is to help arrive at a Go/NoGo decision regarding the candidate product that is being developed. During an experiment or a clinical trial, many data are observed and collected. Then after the study is completed, all of these collected data are available for analysis and interpretation. At this point, the objectives of most of the additional exploratory questions are for signal detection; for example, safety analysis is performed with a hope to see if there is any potential safety concern regarding this test drug (any safety signal?). Subgroup analysis is mostly with a question as to whether any subgroup of patients may demonstrate a high efficacy response, 8, 9 or a safety concern (any signal from a particular subgroup?). Before performing a subgroup analysis, a statistician is inclined to "test and see if there is an interaction."
In general, statisticians are aware of the fact that subgroup analyses are not alpha-protected. Hence, from a regulatory perspective, there is generally not an expectation of "statistical significance" associated with subgroup analyses. In fact, all of the alpha associated with a study is used in the primary analysis of the entire patient set. Hence, in principle, it would not be appropriate to discuss statistical significance or necessarily to provide P values for subgroup analyses. In practice, if a P value of a subgroup comparison is reported, it should be considered merely descriptive. One impression is that the prespecified subgroup analyses tend to be more credible than post hoc subgroup analyses. On this basis, people attempt to overly prespecify. When this is the case, even the prespecified subgroup analyses became lack of credibility.
In general, subgroup analyses are performed with the following possible objectives:
1. to address particular concerns in some specific subgroups; 2. to explore whether the test drug is more efficacious or more harmful to a subset of patients; 3. to demonstrate consistent efficacy across all subgroups; 4. to generate new hypothesis of drug effect; and 5. to address regulatory queries.
The first 4 reasons of performing subgroup analysis can be easily understood. Discussions of this section will now focus on the fifth reason-regulatory queries. Oftentimes in a new drug application (NDA), there is an integrated summary of efficacy (ISE) and an integrated summary of safety (ISS). These analyses are based on combined study results across many clinical trials. When this is the case, the overall sample size is greater than individual studies, and hence there may be sufficient sample size to perform subgroup analysis. Typically the subgroup categories include demographic variables such as age, gender, and race; background variables like concomitant medication usage, disease history, and/or comorbid conditions; or baseline disease severity. Regulatory guidance encourages reporting estimates and CIs for these interaction comparisons. 6 Depending on the disease area and drug class, additional subgroup analyses may be requested by regulatory agencies. Again, the nature of these analyses is exploratory-the interest from a regulatory agency is not about approving the drug for any particular subgroup. This is a signal detection practice.
Recently multiregional clinical trials (MRCTs) have become more popular and they introduce new opportunities and challenges. 10 One of the challenges is to define a criterion to assess the consistency of treatment effect across various regions. In this case, the treatment effect of each region is the mean difference between test drug and control agent within a region, and consistency can be interpreted as lack of interactions between the region of interest and other regions. Under this setting, the local regulatory agency of each country attempts to determine if the treatment benefit of patients within their jurisdiction is consistent with the rest of the world. This is a "we vs they" type of comparison. In this case, a single-degree of freedom treatment-by-region interaction is useful. This interaction compares the treatment benefit of the agency's country and the treatment benefit for the rest of the world:
, with m ij serving as the subgroup mean, where i ¼ 1 is the country of the regulatory agency, and i ¼ 2 represents the rest of world; j ¼ 1 is the test treatment, and j ¼ 2 stands for the control treatment.
At this point, it is more informative to estimate d, than testing to see if d ¼ 0. With a point estimate and an interval estimate on d, it helps the regulatory reviewer to have a better understanding in comparing the treatment effect from their region with the effect from other regions. Furthermore, estimation is flexible because the agency can construct 80%, 90%, 95%, or any other CIs at their discretion.
Although medicinal product approval is a decision-making, or confirmatory, practice, it is not purely made on the statistical basis. In fact, most of the decision-making process where statistical methods are applied, the final decision is very rarely made simply based on the statistical significance. Decision makers usually "study the entire data" before a decision is made. Under this circumstance, point or interval estimates of interactions will be very useful tools to help the decision makers. They are more informative than a single P value.
Chen et al 11 proposes to use Fisher least significant difference for the control of multiple comparison in interaction testing for evaluating consistency. In this manuscript, we hope to argue that a hypothesis test on H 0 : d ¼ 0 is not appropriate, for at least the following 3 reasons. First, the statistical hypothesis testing framework puts the objective into the alternative hypothesis and attempts to negate the null. If the null hypothesis is rejected, then a conclusion can be made such that the study objective is achieved. In the case of local regulatory decision from MRCT, the hope is to achieve consistency, not to conclude inconsistency. On this basis, the null hypothesis should be written in such a way that treatment effects are inconsistent across regions. Hence, the traditional statistical hypothesis testing of "interaction being significant or not" is not appropriate under this setting.
The second reason can be found in Chen et al, 11 which states that for a given MRCT, various regulatory agencies will review the results and many treatment-by-region interactions will be performed. One example is that the "we vs they" type of interaction. If many regulatory agencies perform this type of interactions, there will be multiplicity issues if hypothesis testing is used. However, with point and interval estimations, there is no need to adjust for multiple comparisons.
Finally, in a given MRCT, the study sample size is calculated based on the primary comparison of the primary endpoint. All alphas are used for the powering of the entire study. Typically, there is no alpha prespecified to test an interaction at the design stage. From this point of view, if a 1-degree of freedom treatment-by-region interaction test resulted in a P value of .06, can it be considered as "statistically significant"? Or this can be concluded as "no interaction was detected"?
In recent years, the topic about personalized medicine has become more popular. Many publications discuss how to use subgroup analysis in supporting research in this direction. For example, Zink et al 12 includes references and has a nice example in section 2 discussing interactions and treatment effects among subgroups. In these applications, usually more than 1 factor is considered in the subgroup analysis. Again, these practices are clearly exploratory in nature, and the main objective is signal detection.
Because the nature of subgroup analysis and interaction estimation are both exploratory, it is recommended to provide these estimates using descriptive statistics, or a simple 1-way ANOVA. There is no need to go with sophisticated modeling. In most cases, the interaction of interest can be reduced to a 1-degree of freedom setting: only 4 group means are needed. From a descriptive point of view, each group has a point estimate and a corresponding standard error. These statistics are good enough for estimation of subgroup findings. For the interaction, if a pooled variance is needed, then a 1-way ANOVA with 4 groups (2 treatments by 2 regions, or 2 levels of the stratification factor) provides both point estimates and a common variance estimate. Then, under a contrast statement, the point estimate and CIs for this interaction can be constructed. In practice, overmodeling could be confusing at times.
Higher-Order Interactions
Most statisticians and clinical trialists are familiar with 2-way interactions. As stated earlier, the study of a treatment-bygender interaction is to understand whether treatment benefit for male patients are different from treatment benefit for female patients. However, once a 3-way interaction is introduced, the interpretation becomes less straightforward. For example, in a longitudinal analysis where the study was stratified by gender, the primary analysis model was prespecified as the MMRM model. Discrete main effects in this model include treatment, visit, and gender. The treatment by visit interaction is also used in the primary model.
For exploratory analysis, if a 3-way interaction of treatment by visit by gender was included in this model, all 3 of the 2-way interactions are also included in the model. If a 3-way interaction is significant, how can this 3-way interaction term be interpreted? What does it mean when there is no 2-way interaction but a significant 3-way interaction is detected? Or vice versa, what does it mean when all 3 of the 2-way interactions are significant but the 3-way interaction is not? There are several ways to answer the first question, one of them being that the estimate of a treatment-by-visit-by-gender interaction reflects the different treatment benefit experienced by male and female patients between 2 different visits. Note that this interpretation applies to a single-degree of freedom 3-way interaction-for a given pair of visits, the comparisons between male and female patients in the differences experienced by patients treated with the test treatment and the control. Of course in ordinary studies, a 3-way interaction can be with many degrees of freedom, and for every degree of freedom, a corresponding interpretation can be made.
Regarding the second and the third questions, the focus can still be on a single-degree of freedom interaction testing. In the simplest case, if there is only 1 degree of freedom in the 3-way interaction, that implies each factor has only 2 levels, for all 3 factors. Then all the corresponding 2-way interactions are with a single degree of freedom, also. This 3-way interaction test can be written as
In fact, this hypothesis can be thought of as the difference between 2 of the 2-way interactions of different levels from the same factor. In the case of the 2-way interaction between factors 2 and 3 under factor 1, level 1, and factor 1, level 2, equation (1) 
The answer to the second question is that when hypothesis (1) is rejected, while all 3 of the 2-way interactions are accepted. Similarly, the answer to the third question is that hypothesis (1) is accepted, but hypotheses (2), (3), and (4) are all rejected.
The recommendation for dealing with subgroup analysis and 3-way interaction is still to use descriptive statistics, and 1-way ANOVA. However, in the case when a longitudinal analysis is performed, and that the MMRM is employed to perform data analysis, suppose a regional regulatory agency is interested in the interaction estimate at the primary time point, then a 3-way interaction can be estimated using SAS. The 3-way interaction with treatment by region by visit can be implemented using an ESTIMATE statement where the contrast is being drawn from a study with 4 visits (4 rows) and the primary time point is visit 4, with 2 treatments and 2 regions -PROC MIXED data¼inputdata; Class visit treatment region; Again, when interaction terms are incorporated in a statistical model, the statistician who proposed that model should be knowledgeable about the interpretation of each term, and be able to articulate the implications of all model terms to the nonstatisticians in the study team, as well as in the upper management.
Concluding Remarks
Statistical interaction is not an easy concept for nonstatisticians to understand. Subgroup analysis and interactions appear frequently in clinical trials, and the clinical statisticians often need to communicate these results with nonstatistical team members. In clinical development of new medicinal products, most of the key questions can be divided into confirmatory questions or exploratory questions. Because interactions and subgroup analysis are mainly exploratory, the analytical practice is mostly for exploratory purposes. On this basis, this manuscript proposes not to include treatment by subgroup interaction in the primary analysis model, and for interactions, the recommendation is to use estimation procedures instead of hypothesis testing.
One important application of subgroup analysis is the MRCT. Results from such a study usually are used for submission at various countries across many regions. Each regulatory agency may have an interest in understanding the treatment effect within their country, and the reviewers could request a "we vs they" type of interaction. Under this circumstance, many interactions and subgroup analysis will need to be performed in order to satisfy their requirements. Estimation is a useful tool to help provide this information. There are many reasons why the hypothesis testing is not appropriate. This manuscript proposes not to include treatment-bysubgroup interaction in the primary analytical model, and that either in the protocol or in the statistical analysis plan, a statement could be added such as "treatment-by-region interaction will be explored."
After the data readout, a treatment-by-subgroup interaction can be estimated based on the clinical question of interest: Is there a difference in treatment benefits for those patients from one country as compared to patients from the rest of the world? In order to answer this question, the interaction can be specified as (m test,we -m pbo,we ) -(m test,other -m pbo,other ). A point estimate of such a quantity can be interpreted as the treatment benefit from our country subtracted by the treatment benefit other countries. Then appropriate CIs can be constructed for such a parameter. The more informative presentation could be a sequence of CIs such as 80% CI, 90% CI, 95% CI, and 99% CI. This analysis not only determines the direction of the interaction (more benefit to our country? or more to others?) but also quantifies the interaction. For exploratory or learning purposes, a P value does not offer sufficient information to the regulators.
Clinical statisticians make important contributions to development of new medicinal products. The 2 key tasks are statistical consulting and clinical trial design. In handling interaction terms, if the treatment by subgroup interaction is not included in the primary model, and that the interactions are estimated using simple approaches, then the communications between the clinical statistician and the nonstatistical team members become easier. In this manuscript, the proposed way of handling interactions is that for the primary analytical model, not to include the treatment by subgroup interaction, and then after the primary analysis, interactions are estimated. With this proposal, the study design is very clear, and it could be easier for the clinical statistician to articulate what the interaction is about. When simple statistical models are used in a clinical trial, clear interpretations of study results can be easily communicated to various team members.
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